Levalbuterol tartrate

Levalbuterol tartrate (CAS No.: 661464-94-4) is a synthetic small molecule in the adrenergic agonist class, commonly categorized in respiratory pharmacology and signal transduction research as the pharmacologically active R enantiomer of salbutamol formulated as a tartrate salt, and it is widely used in biomedical studies to interrogate beta2 adrenergic receptor biology, smooth muscle relaxation mechanisms, and crosstalk between cyclic nucleotide and inflammatory pathways. In cell based systems, it functions primarily as a relatively selective beta2 adrenergic receptor agonist that stimulates adenylate cyclase activity, elevates intracellular cyclic AMP, and activates the cAMP PKA signaling axis, with downstream modulation of calcium handling and suppression of contractile responses in stimulated smooth muscle models; published research descriptions also indicate inhibition of PI3K associated signaling with consequent reduction of NF kappa B and Rb related expression patterns in relevant experimental contexts, supporting its use as a mechanistic probe for receptor coupled and kinase linked pathway interactions. Quantitative potency values vary across assay platforms, receptor systems, and species, and where harmonized values are not consistently reported, in vitro activity is generally interpreted within nanomolar to micromolar concentration ranges typical of beta2 receptor agonist profiling and pathway modulation studies. In translationally oriented preclinical workflows, this compound is applied in airway smooth muscle cells, inflammation related cellular assays, and animal models of bronchoconstrictive or hyperresponsive phenotypes to characterize bronchodilatory pharmacology, second messenger dynamics, and target pathway validation, while concentration or dose selection is determined by specific experimental design, model sensitivity, and research objectives in discovery screening or mechanism focused studies.